BiotechTube
Centessa Pharmaceuticals

Centessa Pharmaceuticals

CNTA
London, United Kingdom· Est. 2020

Centessa Pharmaceuticals is a clinical-stage biotech company with a mission to discover and develop transformational medicines for patients. Its core strategy revolves around a portfolio of orexin receptor 2 agonist programs, led by ORX750, targeting significant unmet needs in sleep-wake disorders and broader neuroscience indications. The company is led by a seasoned team of industry veterans and operates with a lean, asset-focused development model to drive programs from discovery to late-stage development efficiently.

centessa.com

CNTA · Stock Price

USD 27.89+13.35 (+91.82%)
Market Cap: $4.2B

Historical price data

AI Company Overview

Centessa Pharmaceuticals is a clinical-stage biotech company with a mission to discover and develop transformational medicines for patients. Its core strategy revolves around a portfolio of orexin receptor 2 agonist programs, led by ORX750, targeting significant unmet needs in sleep-wake disorders and broader neuroscience indications. The company is led by a seasoned team of industry veterans and operates with a lean, asset-focused development model to drive programs from discovery to late-stage development efficiently.

NeuroscienceSleep-Wake DisordersNeurodegenerative DisordersNeuropsychiatric DisordersOncology

Technology Platform

Two core platforms: 1) An Orexin Receptor 2 (OX2R) agonist platform using structure-based drug design for neuroscience, and 2) The LockBody® technology platform, a conditional activation bispecific antibody platform for immuno-oncology.

Pipeline

14
14 drugs in pipeline4 in Phase 3
DrugIndicationStageWatch
SerpinPCHemophilia aPhase 3
LixivaptanPolycystic Kidney Disease, AdultPhase 3
LixivaptanPolycystic Kidney Disease, AdultPhase 3
Lixivaptan + PlaceboAutosomal Dominant Polycystic KidneyPhase 3
SerpinPCHemophilia aPhase 2

Funding History

2
Total raised:$580.4M
IPO$330.4MMay 28, 2021
Series A$250MDec 15, 2020

Opportunities

Centessa's major growth opportunity lies in successfully expanding its OX2R agonist platform beyond sleep disorders into large, underserved neurological and neuropsychiatric markets like Alzheimer's disease-related fatigue and schizophrenia.
Positive data for ORX750 could also attract strategic partnership or acquisition interest from larger pharma companies seeking leadership in neuroscience.

Risk Factors

The company faces significant clinical risk as its value is concentrated on the novel OX2R agonist mechanism; failure of ORX750 in ongoing trials would be catastrophic.
Additionally, regulatory hurdles for first-in-class agents in subjective neurological endpoints and intense competition in the sleep-wake market pose substantial challenges.

Competitive Landscape

Centessa competes in narcolepsy with Jazz Pharmaceuticals (Xywav/Xyrem) and Axsome (Sunosi), but its OX2R agonist is mechanistically differentiated as a potential disease-modifying therapy. In the broader orexin space, it faces Takeda's Belsomra, which works oppositely as an antagonist for insomnia. Its success hinges on proving superior efficacy/safety to current standard-of-care symptomatic treatments.